Let's go back to 2018 for look at my favorite video
This should have gotten an academy award. Proving something works takes time.
Now in the last month we have two announcements that eftilagimod can salvage previous refractory patients treated with pembrolizumab and combination therapy with pembrolizumab is really effective.
What's next?
Merck announces another FDA fast tract study using pembrolizumab with eftilagimod as first line treatment for NSCLC.
Followed by a pembrolizumab and eftilagimod AIPAC treatment arm in June or before.
Ann: Efti with Keytruda shows encouraging activity in lung cancer, page-18
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.005(1.67%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 29.3¢ | $1.323M | 4.421M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 111754 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 61590 | 3 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |